BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 31036052)

  • 1. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
    Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
    Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
    Doherty MR; Cheon H; Junk DJ; Vinayak S; Varadan V; Telli ML; Ford JM; Stark GR; Jackson MW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13792-13797. PubMed ID: 29229854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.
    Smigiel JM; Parameswaran N; Jackson MW
    Mol Cancer Res; 2017 Apr; 15(4):478-488. PubMed ID: 28053127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer.
    Doherty MR; Jackson MW
    DNA Cell Biol; 2018 Jun; 37(6):513-516. PubMed ID: 29750542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.
    Bryson BL; Junk DJ; Cipriano R; Jackson MW
    Cell Cycle; 2017 Feb; 16(4):319-334. PubMed ID: 27892764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer.
    West NR; Murray JI; Watson PH
    Oncogene; 2014 Mar; 33(12):1485-94. PubMed ID: 23584474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.
    Parashar D; Geethadevi A; Aure MR; Mishra J; George J; Chen C; Mishra MK; Tahiri A; Zhao W; Nair B; Lu Y; Mangala LS; Rodriguez-Aguayo C; Lopez-Berestein G; Camara AKS; Liang M; Rader JS; Ramchandran R; You M; Sood AK; Kristensen VN; Mills GB; Pradeep S; Chaluvally-Raghavan P
    Cell Rep; 2019 Dec; 29(13):4389-4406.e10. PubMed ID: 31875548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
    Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
    Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.
    Junk DJ; Bryson BL; Smigiel JM; Parameswaran N; Bartel CA; Jackson MW
    Oncogene; 2017 Jul; 36(28):4001-4013. PubMed ID: 28288136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings.
    Pan CM; Wang ML; Chiou SH; Chen HY; Wu CW
    Oncotarget; 2016 Sep; 7(37):60395-60406. PubMed ID: 27486982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Sonic Hedgehog Signaling Pathway by Thiazole Antibiotic Thiostrepton Attenuates the CD44+/CD24-Stem-Like Population and Sphere-Forming Capacity in Triple-Negative Breast Cancer.
    Yang N; Zhou TC; Lei XX; Wang C; Yan M; Wang ZF; Liu W; Wang J; Ming KH; Wang BC; Xu BL; Liu Q
    Cell Physiol Biochem; 2016; 38(3):1157-70. PubMed ID: 26963129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells.
    Kim YJ; Kim JY; Lee N; Oh E; Sung D; Cho TM; Seo JH
    Biochem Biophys Res Commun; 2017 May; 486(4):1069-1076. PubMed ID: 28373070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX10 induced Nestin expression regulates cancer stem cell properties of TNBC cells.
    Feng W; Liu S; Zhu R; Li B; Zhu Z; Yang J; Song C
    Biochem Biophys Res Commun; 2017 Apr; 485(2):522-528. PubMed ID: 28189679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
    Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
    FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.